In this context, the reduced anti-tumor immunity from sPLA2-IID deficiency is consistent with the concept of the immune checkpoint, which has recently attracted attention in the field of cancer therapy, suggesting that sPLA2-IID may be a novel drug target for skin cancer. The gene discussed is PLA2G2D; the disease is neoplasm.